Myriad Genetics (MYGN) Tops Q1 EPS by 3c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $4.63 +2.89%
Revenue Growth %: -2.7%
Financial Fact:
Net income: -1.2M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -2.7%
Financial Fact:
Net income: -1.2M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $195.9 million versus the consensus estimate of $200.9 million.
GUIDANCE:
Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of $0.08. Myriad Genetics sees FY2025 revenue of $807-823 million, versus the consensus of $916 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Berenberg Starts Natwest Group PLC (NWG:LN) (NWG) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
